Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Incannex Healthcare Ltd ADR (IXHL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/06/2026: IXHL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -49.97% | Avg. Invested days 21 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/06/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 19.05M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2.47 | 52 Weeks Range 0.08 - 3.12 | Updated Date 06/29/2025 |
52 Weeks Range 0.08 - 3.12 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.23 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -20952.04% |
Management Effectiveness
Return on Assets (TTM) -76.74% | Return on Equity (TTM) -201.88% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 14183550 | Price to Sales(TTM) 194.37 |
Enterprise Value 14183550 | Price to Sales(TTM) 194.37 | ||
Enterprise Value to Revenue 144.73 | Enterprise Value to EBITDA -5.13 | Shares Outstanding 93695400 | Shares Floating 28234076 |
Shares Outstanding 93695400 | Shares Floating 28234076 | ||
Percent Insiders 26.14 | Percent Institutions 8.29 |
Upturn AI SWOT
Incannex Healthcare Ltd ADR
Company Overview
History and Background
Incannex Healthcare Ltd. (NASDAQ: INCX, ASX: IHL) is an Australian-based company focused on the development of cannabinoid and psychedelic therapeutics. Founded in 2014, the company has evolved significantly, moving from a focus on cannabis-derived products to a broader therapeutic pipeline that includes novel drug delivery systems and treatments for a range of medical conditions. Key milestones include successful clinical trials, securing regulatory approvals for research and development, and listing on both the Australian Securities Exchange (ASX) and the NASDAQ. Incannex is dedicated to advancing treatments for conditions such as inflammatory lung conditions, pain, and neurological disorders.
Core Business Areas
- Cannabinoid Therapeutics: Development of pharmaceutical products derived from cannabinoids for the treatment of a variety of medical conditions, including inflammatory lung conditions (e.g., asthma, COPD), pain management, and inflammatory bowel disease.
- Psychedelic Therapeutics: Research and development of psychedelic compounds, such as psilocybin and MDMA, for the treatment of mental health conditions like depression, PTSD, and anxiety, in partnership with leading research institutions.
- Drug Delivery Systems: Innovation in novel drug delivery methods to improve the efficacy and patient experience of cannabinoid and psychedelic treatments, such as inhaled formulations.
Leadership and Structure
Incannex Healthcare Ltd. is led by a management team with expertise in pharmaceuticals, biotechnology, and regulatory affairs. Key figures include Joel Betts (CEO), Mark situ00e4 (CFO), and Dr. Mark Miller (Chief Scientific Officer). The company operates with a lean corporate structure, focusing on R&D and clinical trial management, often collaborating with external research organizations and contract manufacturing organizations.
Top Products and Market Share
Key Offerings
- Product Name 1: APIR-001 (Inhaled Cannabinoid for Inflammatory Lung Conditions) - Description: A proprietary inhaled formulation of CBD designed to treat inflammatory lung conditions like asthma and COPD. Competitors: While specific inhaled cannabinoid formulations for these exact indications are emerging, competitors in the broader respiratory drug market include large pharmaceutical companies developing inhaled corticosteroids and bronchodilators. Market share data for this specific product is not yet available as it is in clinical development.
- Product Name 2: TIIS-001 (Psilocybin for Depression) - Description: A psilocybin-based therapeutic candidate for the treatment of major depressive disorder. Competitors: Companies developing psychedelic therapies for depression include Compass Pathways, MindMed, and ATAI Life Sciences. Market share data for this product is not yet available as it is in clinical development.
- Product Name 3: IHL-42X (Cannabis-based treatment for Obstructive Sleep Apnea) - Description: A fixed-dose combination of THC and CBD designed to treat obstructive sleep apnea. Competitors: Established pharmaceutical companies with treatments for sleep apnea include Apnimed and Insys Therapeutics (though with past regulatory issues). Market share data for this product is not yet available as it is in clinical development.
Market Dynamics
Industry Overview
The pharmaceutical and biotechnology sectors are characterized by high R&D costs, long development cycles, and stringent regulatory oversight. The cannabinoid and psychedelic therapeutics market is a rapidly evolving segment within this industry, driven by increasing scientific evidence, patient demand, and evolving legal frameworks. There is significant investment and growing interest in developing novel treatments for unmet medical needs, particularly in mental health and chronic inflammatory diseases.
Positioning
Incannex Healthcare Ltd. is positioning itself as a leader in the development of innovative cannabinoid and psychedelic therapies. Its competitive advantages lie in its unique drug delivery technologies (particularly inhaled delivery), its diversified pipeline targeting significant unmet medical needs, and strategic partnerships with renowned research institutions. The company's dual listing on NASDAQ and ASX provides broader access to capital markets and investor bases.
Total Addressable Market (TAM)
The TAM for cannabinoid and psychedelic therapeutics is substantial and growing. For inflammatory lung conditions, the global market is in the tens of billions of dollars. The global market for depression and other mental health disorders is also in the hundreds of billions of dollars. Incannex Healthcare Ltd. is positioned to capture a share of these markets by developing differentiated and effective treatments. However, as a clinical-stage company, its current market share is effectively zero, with future share dependent on successful clinical development and commercialization.
Upturn SWOT Analysis
Strengths
- Proprietary drug delivery technologies, particularly inhaled formulations.
- Diversified pipeline targeting significant unmet medical needs in both cannabinoid and psychedelic therapy.
- Strategic partnerships with leading research institutions.
- Experienced management team with industry expertise.
- Dual listing on NASDAQ and ASX providing access to capital.
Weaknesses
- Clinical-stage company with no approved products on the market.
- High reliance on clinical trial success and regulatory approvals.
- Significant funding requirements for ongoing R&D and clinical trials.
- Limited brand recognition compared to established pharmaceutical giants.
- Regulatory uncertainty surrounding psychedelic therapeutics in some jurisdictions.
Opportunities
- Growing acceptance and scientific validation of cannabinoid and psychedelic therapies.
- Expansion into new therapeutic indications and geographic markets.
- Potential for strategic collaborations and licensing agreements with larger pharmaceutical companies.
- Increasing patient demand for novel treatment options.
- Favorable regulatory pathways for certain medical conditions.
Threats
- Failure to achieve positive clinical trial results.
- Regulatory hurdles and delays in drug approval processes.
- Competition from established pharmaceutical companies and emerging biotech firms.
- Changes in the legal and regulatory landscape for cannabis and psychedelics.
- Economic downturns impacting investment in speculative biotech companies.
Competitors and Market Share
Key Competitors
- Compass Pathways (NASDAQ: CMPS)
- MindMed (NASDAQ: MNMD)
- ATAI Life Sciences (NASDAQ: ATAI)
- CannTrust Holdings (OTC: CNTTF)
- Aurora Cannabis (NASDAQ: ACB)
Competitive Landscape
Incannex competes in a dynamic and highly competitive landscape for both cannabinoid and psychedelic therapeutics. Its advantage lies in its focus on novel drug delivery systems and a diversified pipeline. However, it faces significant competition from companies with more advanced clinical programs or established market presence in related areas. Regulatory hurdles and the evolving scientific understanding of these compounds also present challenges.
Growth Trajectory and Initiatives
Historical Growth: Incannex's historical growth has been characterized by its strategic expansion of its R&D pipeline, progression through preclinical and clinical development stages, securing significant funding rounds, and achieving dual listing on major stock exchanges. Its growth has been driven by its ability to advance its drug candidates and establish key research partnerships.
Future Projections: Future projections for Incannex are contingent on the successful outcomes of its ongoing clinical trials for its lead drug candidates (e.g., APIR-001, TIIS-001, IHL-42X) and subsequent regulatory approvals. Analyst estimates, if available, would focus on potential market penetration, peak sales, and the timeline to profitability following commercialization. The company's growth is expected to accelerate significantly if key clinical and regulatory milestones are met.
Recent Initiatives: Recent initiatives include advancing clinical trials for multiple drug candidates, forging new research collaborations, and focusing on the regulatory pathways for its psychedelic therapies. The company has also been active in equity markets to secure funding for its development programs.
Summary
Incannex Healthcare Ltd. is a promising clinical-stage biopharmaceutical company with a diverse pipeline of cannabinoid and psychedelic therapeutics, bolstered by innovative drug delivery technology. Its strengths lie in its forward-thinking approach and strategic partnerships. However, the company faces significant risks inherent in drug development, including clinical trial failures, regulatory hurdles, and substantial funding needs. Careful monitoring of clinical trial progress and regulatory developments is crucial for investors to assess its future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company investor relations website
- SEC filings (Form 10-K, 10-Q)
- Financial news outlets
- Biotechnology research databases
Disclaimers:
This information is for informational purposes only and does not constitute financial advice. Stock market investments are subject to risks, and past performance is not indicative of future results. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Incannex Healthcare Ltd ADR
Exchange NASDAQ | Headquaters Sydney, NSW, Australia | ||
IPO Launch date 2022-03-02 | President, CEO & Executive Director Mr. Joel Bradley Latham | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 9 | Website https://www.incannex.com |
Full time employees 9 | Website https://www.incannex.com | ||
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research, development, manufacture, sale, and distribution of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that has completed Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate in Phase 2 clinical trial to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.